论文部分内容阅读
对急性呼吸窘迫综合征（ＡＲＤＳ）的大量研究均表明内源性肺表面活性物质（ＰＳ）系统在其疾病过程中发生功能、结构及代谢的异常，是造成ＡＲＤＳ患者肺功能恶化的重要因素之一〔１〕。外源性ＰＳ替代疗法（ＰＳＲ）在新生儿肺透明膜病（ＲＤＳ）的临床治疗中可改善氧合、降
Numerous studies of acute respiratory distress syndrome (ARDS) have demonstrated that dysfunction, structure, and metabolism of the endogenous pulmonary surfactant (PS) system during the course of their disease are important factors contributing to the worsening of pulmonary function in ARDS patients One [1]. Exogenous PS Replacement Therapy (PSR) Improves Oxygenation in Clinical Treatment of Neonatal Hyaline Membrane Disease (RDS)